These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 263183)

  • 1. The relationship of the basic intellectual endowment of the Parkinson patient to the long-term effect of L-dopa.
    Boshes B; Arbit J; Blonsky ER; Dolkart M
    Int J Neurol; 1979; 13(1-4):181-98. PubMed ID: 263183
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
    Bonduelle M; Degos CF
    Int J Neurol; 1979; 13(1-4):255-61. PubMed ID: 263185
    [No Abstract]   [Full Text] [Related]  

  • 3. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 4. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 5. [Long-term study on the anti-rigidity effect of L-dopa and a decarboxylase inhibitor (ro 8-0576) (author's transl)].
    Eisenlohr JJ; Gehlen W
    MMW Munch Med Wochenschr; 1974 Jul; 116(28):1353-6. PubMed ID: 4212699
    [No Abstract]   [Full Text] [Related]  

  • 6. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
    Ambrozi L; Birkmayer W; Riederer P; Youdim MB
    Br J Pharmacol; 1976 Nov; 58(3):423P-424P. PubMed ID: 791430
    [No Abstract]   [Full Text] [Related]  

  • 8. [Long-term results of L-dopa treatment of parkinsonism].
    Barbeau A
    Union Med Can; 1975 Jan; 104(1):32-8. PubMed ID: 1111195
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
    Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
    Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 12. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R; Schneevoigt K
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract]   [Full Text] [Related]  

  • 13. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of L-dopa on EEG tracings in patients with parkinsonism].
    Rudkowska A; Misztal S
    Pol Tyg Lek; 1975 Apr; 30(14):593-5. PubMed ID: 1129202
    [No Abstract]   [Full Text] [Related]  

  • 15. [Trans-cerebral electrophoresis of L-DOPA in the complex treatment of parkinsonism].
    Neĭmark EZ; Evtushenko SK; Dukhovnaia MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(9):1334-8. PubMed ID: 6506979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of parkinsonism using L-Dopa (Brocadopa)].
    Jörg J
    Med Welt; 1975 Jan; 26(3):124-6. PubMed ID: 1110622
    [No Abstract]   [Full Text] [Related]  

  • 17. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
    Gilligan B; Hancock R
    Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of the preparation L-dopa in parkinsonism].
    Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI
    Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837
    [No Abstract]   [Full Text] [Related]  

  • 19. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy.
    Marini P; Ramat S; Ginestroni A; Paganini M
    Neurol Sci; 2003 Oct; 24(3):184-5. PubMed ID: 14598078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.